Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score 9.11
- Piotroski Score 4.00
- Grade Outperform
- Symbol (AGIO)
- Company Agios Pharmaceuticals, Inc.
- Price $46.70
- Changes Percentage (4.17%)
- Change $1.87
- Day Low $43.25
- Day High $46.79
- Year High $53.29
Agios Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of medicines in the field of cellular metabolism and adjacent areas of biology. The company offers PYRUKYND (mitapivat) an activator of both wild-type and a variety of mutant pyruvate kinase, PK, enzymes for the treatment of hemolytic anemias; and AG-946 that is in Phase I clinical study for treating hemolytic anemias and other indications. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 02/13/2025
- Fiscal Year End N/A
- Average Stock Price Target $53.00
- High Stock Price Target $70.00
- Low Stock Price Target $32.00
- Potential Upside/Downside N/A
- Consensus Rating Buy
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) -$6.31
- Trailing P/E Ratio -7.55
- Forward P/E Ratio -7.55
- P/E Growth -7.55
- Net Income $-352,088,000
Income Statement
Quarterly
Annual
Latest News of AGIO
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
Is suicide contagious? Mental health experts warn of very real risk
By providing your email, you accept Fox News' Terms of Use and Privacy Policy. Suicide, a leading cause of death in the U.S., can be contagious, especially among youth. Experts warn about suicide clus...
By Fox News | 1 month ago -
Agios Pharmaceuticals (AGIO) Appreciated after Positive Testing Results
Meridian Funds, managed by ArrowMark Partners, outperformed the Russell 2500 Growth Index in Q2 2024. The top holding, Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), showed promising growth potential with...
By Yahoo! Finance | 1 month ago -
Agios Pharmaceuticals' tebapivat gains FDA orphan drug designation
Agios Pharmaceuticals received FDA orphan drug designation for tebapivat to treat myelodysplastic syndromes (MDS), aiming to provide a new oral therapy for lower-risk MDS patients. The designation off...
By Yahoo! Finance | 1 month ago
